Clinical Accelerator collaborates with Thrombolytic Science International to study a tPA/mutant pro-urokinase dual regimen for thrombolysis in acute myocardial infarction

Clinical Accelerator, a full-service contract research organization, has entered into a collaboration with Thrombolytic Science International (TSI) to conduct a phase II randomised, multi-centre, open-label, parallel group mechanistic study using TSI’s dual treatment regimen in patients with ST elevation myocardial infarction (STEMI).

The purpose of this clinical trial is to affirm the safety and efficacy of sequential thrombolytic therapy with mutant pro-urokinase and low dose tissue plasminogen activator (tPA) as a potentially safe, simple and early reperfusion treatment for STEMI in comparison with standard of care percutaneous coronary intervention.

TSI’s thrombolytic treatment regimen is based on the endogenous human fibrinolytic system. It uses a low dose of tPA, the approved thrombolytic agent, followed by mutant pro-urokinase, a more stable and safer version of well-studied thrombolytic, pro-urokinase (proUK).

The dual regimen concept was validated in the phase II trial PATENT trial, which showed that a dual treatment of tPA and proUK was more effective and safer than either activator alone.

This novel treatment with mutant proUK is based on the pioneering work of Dr Victor Gurewich, Professor of Medicine at Harvard Medical School, a researcher and a TSI co-founder.

 

This entry was posted in Biotech, Central and Eastern Europe, ClinAccel.Net, Clinical Accelerator. Bookmark the permalink.

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s